Russia Targets Danish Ukraine Suppliers in Sabotage Campaign 
US-Led Coalition Targets Global Factory Overcapacity 
Tsai Warns of China’s Sustained Pressure on Taiwan 
North Korea Slams US Taiwan Arms Sales, Reaffirms Russia Support 
Lincoln University Students Sue Missouri Over Decades of Underfunding 
Mike Rogers Calls for End to US-Canada Tariff War 
Rapidus Seeks Chip Customers as Japan Pushes 2nm Semiconductor Revival 
Zelenskiy Warns Russia Is Preparing Massive Attack on Ukraine 
Mexico Bars Dual Citizens From Presidential Races Starting in 2028 
JD Vance Says Iran Must Cut Nuclear Enrichment to End War 
Trump Says He Deserves 2026 Nobel Peace Prize Despite Uncertain Chances 
SEC Investor Reform Validates Barry Silbert’s Tokenization Vision 
Crypto Lobbying Hits $13M as Clarity Act Stalls 
Houthis Strike Aden Airport as Yemen Fighting Escalates 
US, Greece Launch New Counterterrorism Security Program 
Fairshake Backs 32 Pro-Crypto House Candidates 
Add as a preferred source on Google
The United States has opened a Section 301 trade investigation into Germany’s proposed efforts to reduce pharmaceutical spending, raising concerns that the measures could unfairly impact American drugmakers and innovative pharmaceutical products.
U.S. Trade Representative Jamieson Greer announced on Thursday that the investigation will examine whether Germany’s healthcare reform plans are unreasonable or discriminatory under U.S. trade law. The probe is being conducted under Section 301 of the Trade Act of 1974, a tool Washington has frequently used to address trade practices it considers harmful to U.S. businesses.
According to Greer, the Office of the U.S. Trade Representative (USTR) will begin accepting public comments on June 25, while a public hearing before the Section 301 Committee is scheduled for September. The investigation follows reports that Germany is considering legislation aimed at lowering healthcare costs, including spending on prescription medicines.
“I am particularly concerned with news that Germany is fast-tracking legislation that would further reduce its spending on innovative pharmaceuticals,” Greer said.
The move comes after Germany’s Health Ministry unveiled a broad healthcare reform proposal in April designed to address an estimated €20 billion ($23 billion) funding shortfall in the country’s statutory healthcare system. The original plan included variable discounts on pharmaceutical products, a measure that faced strong opposition from the pharmaceutical industry.
A German government source recently told Reuters that the proposal involving variable drug discounts is being replaced following industry backlash. Germany’s embassy in Washington has not yet commented on the U.S. investigation.
The probe reflects the Trump administration’s broader trade strategy, which has relied heavily on tariffs and trade enforcement actions. Since returning to office, President Donald Trump has introduced a 10% global tariff and threatened additional tariffs on imports from several countries.
If the investigation concludes that Germany’s pharmaceutical pricing policies harm U.S. interests, Washington could impose tariff-related measures on German imports, potentially adding new tensions to U.S.-Germany trade relations.
